Tanvi Sood
Shri Ram Murti Smarak Institute of Medical Sciences, India
Scientific Tracks Abstracts: J Cancer Sci Ther
Introduction: Multiple myeloma is a neoplastic disorder characterized by proliferation of a single clone of plasma cells leading to varied clinical presentations. Various clinical and laboratory parameters have been established as prognostic factors but their correlation with staging systems has been sparingly studied in Indian population. Materials and Methods: A retrospective study was done over a period of 30 months at a tertiary care centre including 33 patients of Multiple Myeloma. Physical examination, radiological investigations and routine laboratory investigations including bone marrow examination, serum protein electrophoresis and serum �²2-microglobulin levels were recorded. Patients were staged according to the Durie-Salmon Staging System (DSS) and the International Staging System (ISS) and correlation between prognostic markers and clinical stage was studied. Results: A total of 33 patients were included in the study, all of whom had M-band in the gamma region on serum protein electrophoresis. 51.5% patients presented with renal failure and its presence correlated positively with the stage of disease (0.643, P<0.001). Plasmacytosis showed a positive correlation with the stage of disease (0.351, p<0.045). A significant positive correlation was also found between the DSS and ISS (0.575, p<0.001). Haemoglobin, Serum �²2-microglobulin levels, advanced age, Estimated Sedimentation Rate (ESR), serum creatinine and uraemia were other factors that significantly correlated with the clinical stage in our population. Conclusion: Both ISS and DSS correlate well as staging systems for Multiple Myeloma in the Indian population. Routine investigations like Haemoglobin, ESR, renal function tests and plasma cell percentage can be used for prognostication at initial presentation. Prognostic markers like serum �²2-microglobulin and renal failure are strongly associated with more advanced stages of Multiple Myeloma.
Tanvi Sood finished her MBBS course from Bharati Vidhyapeeth University, Pune, India in the year 2013. She is currently pursuing Masters in Internal Medicine at SRMSIMS, Uttar Pradesh, India. She has been awarded Gold prize and rewarded scholarship for her academic achievements and scientific presentations, both National and International. Her work has been accepted and published in national as well as international journals. She was part of the Organising Committee of the International Conference MEDICINE UPDATE 2015 held at Bareilly, India. She has also participated in Phase 3 drug trials while working at Dr. Ram Manohar Lohia Hospital, PGIMER, New Delhi. She has special interest in Oncology and Endocrinology.
Email: tanvi_sood@yahoo.com
Cancer Science & Therapy received 5332 citations as per Google Scholar report
Spanish 
Chinese 
Russian 
German 
French 
Japanese 
Portuguese 
Hindi 